Drugs / Hetrombopag Olamine

Trials 4 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT06478537 Jun 2024 → Jun 2027 expected thrombocytopenia due to immune destruction Peking Union Medical College Hospital Recruiting No outcome recorded
Phase 2 NCT05944211 Jul 2023 → Jul 2026 overdue thrombocytopenia RenJi Hospital Not yet recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT07286032 Apr 2026 → Dec 2028 expected thrombocytopenia Jiangsu HengRui Medicine Co., Ltd. Recruiting No outcome recorded
Phase 41 trial
Phase 4 NCT05575986 Oct 2022 → Oct 2023 digestive system cancer, thrombocytopenia Huazhong University of Science and Technology Unknown No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03603132 Comparator Jul → Aug 2018 autoimmune thrombocytopenia Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Hetrombopag Olamine ClinicalTrials.gov intervention name — accepted as the source's own label NCT03603132
4

NCT06478537

NCT07286032

NCT05575986

NCT05944211

Known as Hetrombopag diolamine ChEMBL registry synonym — accepted as the source's own label CHEMBL4297764
Known as Hetrombopag ethanolamine ChEMBL registry synonym — accepted as the source's own label CHEMBL4297764
Known as Rafutrombopag olamine ChEMBL registry synonym — accepted as the source's own label CHEMBL4297764
Known as SHR-8735 OLAMINE ChEMBL registry synonym — accepted as the source's own label CHEMBL4297764
Action Activate “Thrombopoietin receptor agonist” CHEMBL4297764
Route Oral “single oral dose” NCT03603132
Target MPL “Thrombopoietin receptor agonist” CHEMBL4297764